4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0001577014-26-000008
Director sold 106,723 shares at an average $18.14 ($1,936,341)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Rhodes Jason P Director | 2026-05-04 | Sale 10b5-1 | −3,136 | $18.00 | $56,448 | 1,574,270 | I |
| Rhodes Jason P Director | 2026-05-04 | Sale 10b5-1 | −6,241 | $18.00 | $112,338 | 4,933,196 | I |
| Rhodes Jason P Director | 2026-05-04 | Sale 10b5-1 | −61 | $18.00 | $1,098 | 8,450 | I |
| Rhodes Jason P Director | 2026-05-04 | Sale 10b5-1 | −2,466 | $18.00 | $44,388 | 1,156,457 | I |
| Rhodes Jason P Director | 2026-05-05 | Sale 10b5-1 | −3,056 | $18.03 | $55,100 | 1,571,214 | I |
| Rhodes Jason P Director | 2026-05-05 | Sale 10b5-1 | −6,081 | $18.03 | $109,640 | 4,927,115 | I |
| Rhodes Jason P Director | 2026-05-05 | Sale 10b5-1 | −60 | $18.03 | $1,082 | 8,390 | I |
| Rhodes Jason P Director | 2026-05-05 | Sale 10b5-1 | −2,403 | $18.03 | $43,326 | 1,154,054 | I |
| Rhodes Jason P Director | 2026-05-06 | Sale 10b5-1 | −21,926 | $18.18 | $398,615 | 1,549,288 | I |
| Rhodes Jason P Director | 2026-05-06 | Sale 10b5-1 | −43,621 | $18.18 | $793,030 | 4,883,494 | I |
| Rhodes Jason P Director | 2026-05-06 | Sale 10b5-1 | −428 | $18.18 | $7,781 | 7,962 | I |
| Rhodes Jason P Director | 2026-05-06 | Sale 10b5-1 | −17,244 | $18.18 | $313,496 | 1,136,810 | I |
| Open-market sales · 106,723 sh · avg $18.14 · $1,936,341 | |||||||
Loading xslF345X06/form4-05062026_090534.xml…